Daily Stock Analysis, CORI, Corium International Inc, priceseries

Corium International Inc. Daily Stock Analysis
Stock Information
Open
12.67
Close
12.68
High
12.74
Low
12.65
Previous Close
12.65
Daily Price Gain
0.03
YTD High
16.29
YTD High Date
Aug 3, 2015
YTD Low
2.67
YTD Low Date
Feb 6, 2017
YTD Price Change
4.68
YTD Gain
58.50%
52 Week High
12.74
52 Week High Date
Nov 26, 2018
52 Week Low
12.65
52 Week Low Date
Nov 26, 2018
52 Week Price Change
0.00
52 Week Gain
0.00%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 15. 2017
3.19
Mar 2. 2017
3.69
10 Trading Days
15.68%
Link
LONG
May 10. 2017
4.73
Jun 7. 2017
7.01
19 Trading Days
48.30%
Link
LONG
Jul 5. 2017
7.95
Jul 21. 2017
8.88
12 Trading Days
11.68%
Link
LONG
Aug 23. 2017
7.77
Oct 9. 2017
10.68
32 Trading Days
37.42%
Link
LONG
Jan 11. 2018
11.17
Jan 31. 2018
12.98
13 Trading Days
16.17%
Link
Company Information
Stock Symbol
CORI
Exchange
NasdaqGM
Company URL
http://www.coriumgroup.com
Company Phone
650-298-8012
CEO
Peter D. Staple
Headquarters
California
Business Address
235 CONSTITUTION DRIVE, MENLO PARK, CA 94025
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001594337
About

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes of specialty pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1995 and is headquartered in Menlo Park, CA.

Description

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, that has completed Phase III clinical trial to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trial for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trial for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Ropinirole TDS that is in preclinical stage for the treatment of Parkinson's disease; MicroCor Zolmitriptan that is in preclinical stage for treatment of migraine; and generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements primarily with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Endo Pharmaceuticals, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.